Patent ID: 8691183
Filing Date: 2014-04-08
Classification: A61P,G01N

Abstract:
1. A method for manufacturing a composition for identifying and treating prostate cells comprising a) providing a ligand of lilly-of-the-valley odorant receptor (OR17-4), wherein the ligand of OR17-4 is undecylic aldehyde, and b) formulating said ligand of OR17-4 into a pharmaceutically acceptable carrier, wherein the composition further comprises a marker selected from the group consisting of a fluorescence marker detectable by means of fluorescence microscopy, wherein the fluorescence marker is selected from fluorescein isothiocyanate (FITC), rhodamine, rhodamine isothiocyanate (RITC), sulforhodamine B, dansyl chloride, fluorescamine, green fluorescent protein (GFP), ethidium bromide, 4′-6-diamidino-2- phenylindole (DAPI), coumarin, luciferase, phycoerythrin (PE), Cy2, Cy3.5, Cy5, Cy7, texas red, alexa fluor, fluor X, red 613, BODIPY-FL, TRITC, and DS red, a magnetic resonance tomography (MRT) marker detectable by means of magnetic resonance tomography (MRT), wherein the MRT marker comprises a complexing agent for metals and a complexed metal, said complexed metal is selected from gadolinium (Gd), europium (Eu), gallium (Ga), manganese (Mn), iron (Fe), yttrium (Y), and its isotopes, a computer tomoraphy (CT) marker detectable via computer tomoraphy, wherein said CT marker comprises an iodine compound selected from iopromide, thyroxine, triiodothyronine, and triiodobenzoic acid, and a radioactive marker detectable by means of nuclear medical methods, wherein the radioactive marker is the γ-radiator gadolinium-153 or a β-radiator selected from Sr-89, Y-90, 1-131, Er-169, Re-186, and Re-188.